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ABSTRACT  
Mycobacterium tuberculosis, commonly referred to as TB, is responsible for causing 
about 630,000 cases per year of infectious diseases worldwide.  Recently, multidrug resistant 
tuberculosis (MDR-TB) has become an alarming public health concern. In addition, many 
developing countries lack effective treatment programs. India is one of those countries with a 
high prevalence of TB, seemingly affected by disconnectedness in their public health 
infrastructure. India, although a developing country, is still burdened with both chronic and 
infectious diseases, and there is a reactive public health system that must place focus on long-
term effects of emerging resistant strains of TB.  It is important to develop rapid drug 
susceptibility testing for quick diagnosis and treatment of monitored TB levels. According to a 
2013 article published by Lancet, countries with well-run public health programs, supported by 
early diagnosis and access to quality drugs, have better treatment outcomes and compliance. 
Compliance must be maximized in developing countries to prevent the continuing emergence of 
MDR-TB. India’s public health infrastructure must be reshaped and empowered with 
implementation of treatment programs and surveillance frameworks similar to those seen in 
countries with low rates of MDR-TB levels. It is important that India strengthen their framework 
for combating MDR-TB, with emphasis on increasing health literacy among community leaders, 
informing government agencies of the necessity of research and surveillance, strengthening rapid 
TB diagnostic systems, and providing culturally-appropriate TB treatment programs. Using 
intervention strategies from other communities may help India develop an appropriate solution 
for decreasing the prevalence of MDR-TB.  
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INTRODUCTION  
 Infectious diseases are at the dawn of a new era where strains are becoming resistant to 
medications that have been used for decades. However, emerging strains with resistance to 
medications may be prevented through public health measures. Specifically, multidrug resistant 
tuberculosis (MDR-TB) is of particular concern to public health officials throughout the world. 
Surveillance of MDR-TB is especially important in the four major economically developing 
countries, referred to as BRIC: Brazil, Russia, India, and China (Lancet, 2013). An evaluation of 
the current TB epidemic will be specifically completed in relation to India. Importantly, as India 
develops into a booming economy, there is a need for more investment and government funds to 
build the public health infrastructure, in order to decrease the rapidly increasing rates of MDR-
TB. Another important factor in combating the current TB epidemic in India is a commitment to 
MDR-TB treatment programs.  
 Tuberculosis is an aerosol transmitted infectious disease. That is to say, a person 
suffering from TB may easily transmit the bacterium through air droplets or a hacking cough. 
The transmission of the bacterium is particularly problematic in areas with dense populations, 
such as the overpopulated areas of India. According to the Centers for Disease Control and 
Prevention (CDC), TB usually affects the lungs; however, there can be metastasis to the brain, 
kidneys, or the spine. The adverse effects of TB are exacerbated most when the wrong treatment 
is given. If an inappropriate course of treatment is given, that is either too short or missing an 
active ingredient, the strain of bacterium develops resistance, and this form is regarded as 
multidrug-resistant tuberculosis. 
 In the same way that TB is transmitted through the air, so are MDR-TB pathogens 
(Drlica, 2011). During outbreaks of tuberculosis there is an increased risk for the transmission of 
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antibiotic resistant pathogens. Consequently, “when a strain of TB acquires resistance to the two 
main antituberculosis drugs, currently rifampin and isoniazid, the strain [becomes MDR-TB]” 
(Drlica, 2011, p. 111). Without a doubt, MDR-TB is a global threat due to its aerosol 
transmission and aggressive nature when treated improperly. At the point of antibiotic resistance, 
there are limited agents for treatment. In addition, “accumulation of additional resistance 
mutations leads to extensively resistant (XDR-[TB])” (Drlica, 2011, p. 111), which is rendered 
almost untreatable. Unquestionably, high prevalence rates of TB and MDR-TB in developing 
countries must be addressed with the primary goal of avoiding a high percentage of their 
population being resistant to any type of treatment.   
 There is a specific focus on appropriate and effective treatments for tuberculosis (TB) 
due to the pathological nature of this infectious disease. As referenced earlier, an individual 
infected with TB and inadequately treated will develop resistance to first-line antibiotics. 
Unfortunately, due to the lack of communication between private and healthcare institutions in 
India, there exist some of the highest worldwide percentages for MDR-TB because first-line 
drugs are being distributed but TB treatments are not being monitored, with the result being 
MDR-TB. The problem with the high rates of MDR-TB, aside from being a communicable 
infectious disease, is the need for expensive, lengthy, and aggressive treatments.  
 Among the risk factors for acquiring MDR-TB are overpopulation, poverty, low health 
literacy, and inadequate courses of treatment for already infected TB patients. Also, outside of 
the United States, TB is the number one opportunistic infection for patients who are HIV 
positive. Mortality rates therefore increase due to co-infections of TB and HIV. Particularly 
alarming are the statistics that demonstrate that TB in the United States is increasingly found in 
foreign-born persons (National TB Surveillance System, 2012). Most of the cases of TB that 
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have caused panic in the U.S. have been imported from other countries but have been rapidly 
treated. The reason that the U.S. TB rates have remained low among the general population is 
due to the strong public health infrastructure and more significant funds contributing to 
surveillance and monitoring of emerging diseases. However, with increased globalization and 
tourism, strains of MDR-TB are increasing at rates that may not be as quickly diagnosed and 
treated. The World Health Organization (WHO) estimates there are roughly 630,000 cases per 
year of tuberculosis worldwide, with prevalence of multi-drug resistant tuberculosis rising.  
THE PROBLEM 
 Although ranked “the fifth largest economy in the 21st century” (John, 2011, p. 252), 
India is facing the threat of an uncontrolled MDR-TB outbreak among their rural and urban 
populations. There is a lack of data regarding the exact percentage of persons in India affected 
with MDR-TB due to poor diagnostic and surveillance systems. Despite the lack of data, the 
prevalence of TB itself cannot be denied, and India’s public health infrastructure must be 
reshaped in order to best serve the emerging diseases sector. According to an annual emerging 
diseases series published by Lancet, “the cause of this deficiency is the health system…[lacking] 
an adequately functional public health infrastructure that is essential for prevention of disease in 
all communities” (John, 2011, p. 252). In effect, a lack of surveillance in all communities leads 
to skewed data, presenting numbers that consider only parts of a threatening TB outbreak. 
Furthermore, India’s current surveillance system for infectious diseases must be updated and 
integrated to create communication between all states and the federal health department. 
Reshaping an integrated surveillance system for infectious diseases will allow more prompt 
diagnostic services and minimize the amount of time between diagnosis and treatment. In order 
to accomplish an effective surveillance system, policy makers must be informed about the 
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threatening health results of MDR-TB. In order to adapt a more effective framework for the 
public health issue of MDR-TB in India, their current TB intervention programs must be 
reevaluated. Proliferating intervention programs of other countries, with similar demographics 
and risk factors, should be assessed for guidance in reconstruction. The objective of evaluating 
example intervention programs is to build an integrated surveillance system that would allow for 
prompt diagnosis and appropriate TB courses of treatment, with regulation of pharmaceuticals. 
Furthermore, based on evaluated programs, there is a need to increase the health literacy among 
communities in order to minimize the relapse of first-line TB treatments.  
REVIEW OF LITERATURE 
Infectious diseases worldwide 
The challenge for the current global health agenda is dealing with an epidemic of 
infectious diseases worldwide. Furthermore, disease outbreaks become difficult to control in 
countries that do not properly diagnose and report these outbreaks (Christian et al., 2013). As a 
result, the inability to contain such diseases threatens to cause an inception of newly antibiotic 
resistant pathogens. Pathogens that become resistant to typical courses of treatment are equally 
as infectious as their counterparts and spread in a similar manner (Drilca, 2011). Eventually, all 
available antibiotics become ineffective in treating dangerous pathogens. In a 2013 article, in 
Emerging Health Threats, the Centers for Disease Control and Prevention’s (CDC) Global 
Disease Detection (GDD) Operations Center identified five of the emerging pathogen threats as 
avian influenza A (H5N1), cholera, wild poliovirus, enterovirus-71, and extensively drug-
resistant tuberculosis (Christian et al., 2013).  The infectious diseases were identified according 
to the following factors: “high transmissibility, disease burden and severity; established or 
pandemic potential; disease eradication; and lack of available preventative or treatment 
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interventions” (Christian et al., 2013). Lack of available intervention programs is of particular 
importance for low-socioeconomic regions where there are insufficient clinics, hospitals, and 
laboratory resources. Also, transmissibility of diseases is of important concern in current society 
where global mobility is allowing for pathogen translocation from one area to another (Hartley et 
al., 2010). For this reason, the goal of surveillance, diagnosis, and treatment programs is to 
contain diseases at their local origin, with the purpose of preventing a global threat of disease.  
 
Global program initiatives for infectious diseases 
Consequently, global health initiatives have implemented various prevention programs in 
countries that are most burdened by infectious diseases. According to Dr. Margaret Chan, 
director general of the World Health Organization (WHO), “When the world is collectively at 
risk, defense becomes a shared responsibility of all nations” (World Health Day, 2007). Indeed, 
WHOs integrated network is part of formulating important tasks for its representative countries. 
Furthermore, responsibilities of countries are outlined in places such as the annual United 
Nations Millennium Development Goals (MDGs) Report, where obstacles, expectations, and 
great visions are established for combating global inequities. The MDGs were established during 
a 2000 conference where 191 United Nations’ member states declared to bring a taskforce 
against the following eight global disparities: poverty, hunger, disease, illiteracy, environment 
sustainability, and women’s rights (United Nations, 2013). The forthcoming targets are to be met 
by 2015. Furthermore, enforcing and regulating health care measures is greatly affected by a 
country’s already established health institutions. Gathered data results in either further action or a 
reconstruction and review of both the MDGs as well as the country’s health institution programs 
that may seem to struggle with combating the problem.  
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Global Tuberculosis Warning 
Currently, one third of the world’s population is infected with Mycobacterium 
tuberculosis (M.tuberculosis) (Tille, 2014). Tuberculosis (TB) is currently an infectious disease 
of global concern because its “incidence rate is falling at less than 1% per year,” and nearly 9 
million cases are being reported each year (Lönnroth et al., 2010, p. 1814). The fight against the 
global TB epidemic has led to many established global health programs. Some examples of well-
known TB prevention, diagnosis, and treatment programs are as follows: WHO’s Stop TB 
Strategy and Global Plan; Center for Disease Control and Prevention (CDC) National TB 
Performance Targets for 2015; basic National TB Programs (NTPs); and most importantly the 
Directly observed Treatment Short-course (DOTS) strategy (World Health Organization, 2012). 
In addition, the MDGs for 2050- established as post-2015 goals- present an overarching goal of 
decreasing TB incidence rates to less than one case per million (Lönnroth et al., 2010, p. 1814). 
In order to meet the target, WHO recommends that all of the member states assess their current 
TB programs with the objective of building the most effective healthcare intervention programs. 
 
Directly Observed Treatment Short-course (DOTS) Strategy Defined 
 DOTS is the core component of WHOs Stop TB Strategy. The vision of WHO is to 
eliminate TB as a public health problem by 2050 (WHO, 2013). Achieving WHOs target 
requires proper treatment of TB. Treatment for TB is complicated and DOTS was developed for 
ensuring that diagnosed patients take the correct medications in proper doses (WHO, 2012). 
Primarily, a healthcare worker visits the patient at their home or workplace, for the purpose of 
ensuring complete adherence. Furthermore, each visit is documented until the TB treatment 
course is completed. Also, it is important to recognize that DOTS is used for treating patients 
MULTIDRUG-RESISTANT TUBERCULOSIS IN INDIA 9 
with diagnosed TB and DOTS-Plus is the program used for treating multidrug-resistant TB. 
DOTS-Plus was established for ensuring reduced fees on second-line treatment drugs, which are 
often very costly and disproportionately affect populations of lower socioeconomic status (Stop 
TB Partnership, 2006). Every location implements DOTS and DOTS-Plus according to their 
demographics and treatment completion rates. Recently, barriers have risen for treating MDR-
TB due to lack in laboratory technology, quick drug susceptibility testing (DST), and inception 
of second-line drug resistance (XDR-TB). In effect, countries must assess their healthcare 
facilities to ensure that qualifying diagnosed TB/MDR-TB patients are receiving adequate 
treatment courses from DOTS/DOTS-Plus. Also, WHO must ensure that its partners are creating 
community consciousness regarding the availability of DOTS TB treatments.  
 
Tuberculosis: Symptoms and Progression 
To further illustrate the threat of TB, there is a necessity to understand and describe the 
epidemiology of such a communicable disease. Tuberculosis is caused by a pathogenic 
bacterium called Mycobacterium tuberculosis (M. tuberculosis), and it has the ability to 
contaminate individuals through airborne means when someone coughs or sneezes and transmits 
infected nuclei droplets (Tille, 2014). Usually, a person with a healthy immune system is able to 
fight minimal exposure to a TB germ, but continual exposure poses a serious threat by 
compromising a healthy system and lungs. Once someone becomes infected with TB, the 
infection may become either latent or active. Usually, latent TB remains inactive and the 
individual poses no symptoms or threat to others unless their immune system becomes 
compromised and the TB pathogen becomes activated. In the active form, TB infects the human 
host in a progression of weeks or months, depending on the person, and presents itself in the 
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form of an infectious tubercle. A TB tubercle infects its host by releasing the bacterium into the 
lungs, which causes a progression of inflammation, scarring, granulation, and necrosis of 
normally sterile lung tissue. Delayed diagnosis of TB results in the debilitating progression of 
TB. Some general symptoms identified in pulmonary TB are as follows: unexplained weight 
loss, loss of appetite, night sweats, fever, and fatigue. Generally, a more conclusive diagnosis of 
TB is reached with more advanced symptoms, where the patient presents with a 3-week 
prolonged cough having sputum discharge, possibly with blood, and having chest pain with 
shortness of breath (Tille, 2014). Regardless of identifiable symptoms, a TB diagnosis is not 
certain unless laboratory analysis is done to test for the bacteria, hence the delay between 
diagnosis and treatment in low socioeconomic regions that lack quick diagnostic technology. 
 
Tuberculosis: Diagnosis 
It is estimated that in developing or underdeveloped countries “fewer than half of patients 
are correctly diagnosed with TB the first time they seek help” (Dyer, 2010, p. 16). In more 
developed countries such as the United States, screening for TB is accomplished with the 
Mantoux skin test, a test that most people are required to get every two-years due to school or 
employment regulations. The typical results from the Mantoux test are noticeable within 48 to 72 
hours, and health care providers identify the presence of TB depending on spot diameter and skin 
inflammation or elevation. A positive TB-skin test results in further laboratory diagnostic testing 
of the patient’s sputum to confirm a diagnosis. In contrast to the U.S., developing countries 
actually vaccinate babies at birth with the Bacillus Calmette-Guérin (BCG) vaccine (Reichman 
& Tanne, 2002). The BCG vaccine is not used in the U.S. because TB is not endemic there and 
the effectiveness of the vaccine is questionable. Moreover, other diagnostic measures used for 
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identifying TB are a blood test, QuantiFeron-TB Gold (QFT-G) or a chest X-ray (Tille, 2014). 
However, neither of these gives a definite TB diagnosis, nor do they completely quantify the 
extent to which the TB bacterium has progressed. The only definitive diagnosis for TB is done in 
labs equipped for the microbiologic procedure of acid-fast bacteria staining and culture (Dyer, 
2010). Sputum samples are collected from identified patients, and laboratory professionals use 
specialized biohazard-containment environments to best incubate the slow growing TB bacteria 
(Chiang, Van Weezenbeek, Mori, & Enarson, 2013). However the methods for definitive 
identification, diagnosis, and antimicrobial susceptibility testing are lengthy, which affects 
timely treatment. 
 
Tuberculosis: Treatment 
Delays in treatment can result in less effective opportunities for cure as well as higher TB 
risk for the patient’s surrounding community.  Overall, diagnosis and immediate treatment rely 
on access to adequate healthcare in order to prevent the progression of TB infection. In treating 
TB, it is the cellular structure of the bacteria that poses difficulty due to a cell wall that acts as a 
barrier to antibiotic drugs. Additionally, the TB bacterium quickly adapts and develops resistance 
to virtually all effective drugs (Tille, 2014). Treatments for promptly diagnosed TB consist of a 
combination of first-line antibiotics, namely isoniazid and rifampicin (Vassal et al., 2011). The 
length of an effective treatment for a TB treatment course lasts around six to nine months (Dyer, 
2010). Treatments given for too short of a time period or with the wrong combination of 
antibiotics will indeed result in TB known as multidrug-resistant tuberculosis (MDR-TB). The 
length of an effective treatment for MDR-TB is an estimated two years of multiple drug 
combinations (Farmer, 2003). Additionally, what are known as second-line drugs for treating 
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MDR-TB are more toxic, expensive, and less effective in curing the patient (Dyer, 2010). 
Unfortunately, MDR-TB has become a worldwide problem and WHO reports that from 2008 to 
2010 there was an increase in the number of cases from 29,000 to 53,000, respectively 
(Raviglione et al., 2012). However, due to a dearth in available drug susceptibility, it is believed 
that these numbers represent just one-fifth of the world’s actual MDR-TB cases (Raviglione et 
al., 2012). Globally, certain locations suffer more disproportionately from MDR-TB than others. 
As is expected, these areas are those also affected by their large TB prevalence and in need of 
intervention strategies that will allow for reliable diagnostic tests, prompt treatments, and well-
constructed health programs for infection control.  
 
India’s Prevalence of Tuberculosis 
Presently, the country of India is of particular concern for their prevalence of MDR-TB. 
Overall, infectious diseases continue to be an urgent subject matter for the healthy outcomes of 
their citizens. Despite India’s economic development, infectious diseases still contribute 30% of 
the disease burden in India (John, 2011, p. 252). Some preventable infectious diseases currently 
threatening India’s public health are malaria, filariasis, visceral leishmaniasis, leprosy, HIV, and 
last, but not least, tuberculosis (John, 2011, p. 252). In 2011, WHO estimated 12 million 
prevalent cases worldwide, with 40% of TB cases being from India and China (Porwal, et al. 
2013). These two countries are also responsible for roughly 50% of all global MDR-TB reported 
cases (Maurya et al., 2013). Furthermore, although there is not enough accurate data regarding 
the total number of MDR-TB cases, hospitals of India have reported some TB cases that have 
included both MDR-TB and XDR-TB. Tuberculosis and the other preventable infectious 
diseases may be decreased in prevalence with more suitable and updated disease control 
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programs. The challenge, however, is India’s health system, where disease control programs are 
not integrated nor do they function as a system. Rather, selected diseases are prioritized and 
special programs are autonomously implemented in burdened districts (John, 2011). The gap in 
communication between programs may limit accessibility regarding important disease outbreaks 
or innovative diagnostic services and treatment solutions. In effect, undertaking the challenge of 
constructing an effective infection control program for India will require reevaluation of current 
risk factors for prevalent diseases such as TB. An effective TB program should be implemented 
for India, in order to lessen the possibility of an uncontrollable MDR-TB outbreak.  
 
India’s TB Program 
 Currently, India’s more recognized TB intervention program is the Revised National 
Tuberculosis Control Program (RNTCP). This program is considered a National TB Program 
(NTP) and is partnered with WHO with the objective of delivering the DOTS strategy to TB 
infected individuals (Goodchild et al., 2011). The program reached geographical coverage of 
India in 2006 (Goodchild et al., 2011). Importantly, RNTCP treatment programs are provided 
free of cost by health facilities and follow the DOTS program dosage three times a week under 
the supervision of a healthcare worker (Satyanarayana et al., 2011). However, many patients 
further seek cure from private healthcare facilities, believing the treatment is lengthy and not as 
personalized as private care. Compliance often fails with RNTCP alone, hence the reason that 
health literacy about TB and MDR-TB should be increased in TB affected areas. This is evidence 
that RNTCP drug treatment alone is not sufficient in treating TB in locations where diseases are 
exacerbated by socio-environmental factors.  Furthermore, there is minimal data regarding the 
prevalence of TB-infected individuals outside of the RNTCP program, because those individuals 
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are seen by private sectors of India’s healthcare system. Some recently published reports 
consider the emergence of MDR-TB to be roughly 110,000 cases spread across the country but 
an actual national report has not been completed (Maurya et al., 2013). Having reviewed the 
prevalence of TB in India and the program working to combat this disease, recognition of 
underlying socio-environmental factors is necessary. 
 
Tuberculosis: A “social disease”? 
In 1952, René Jules Dubos (1901-1982), a microbiologist, published The White Plague: 
Tuberculosis, and described tuberculosis as a “social disease” (Dyer, 2010). Dubos claimed that 
the solution for understanding tuberculosis was beyond the scope of traditional medicine. As 
referenced previously, factors that magnify the communicability of these bacteria are 
socioeconomic factors such as poverty, leading to poor sanitation, overcrowding, unhealthy 
living conditions, and malnourishment (Lönnroth et al., 2013). In addition, TB is the primary 
opportunistic infection in HIV patients in many developed and underdeveloped countries, where 
co-infection forms a significant population percentage (Swaminathan & Narendran, 2008). 
Globally, HIV and TB are the two more common causes of population mortality, with HIV being 
the most common. Furthermore, HIV/AIDS compromises the immune system, which makes a 
TB-infected individual more susceptible to the debilitating factors from the disease. Thus, 
developing intervention programs that control both medical and socio-environmental risk factors 
can allow for more substantial progress in the fight against TB.  
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India’s Healthcare System 
 In addressing disease and social inequalities in India, it is important to recall the 
interconnectedness between a communicable pathogen, susceptible host, and incubating 
environment (Atre & Mistry, 2005). The conducive environment, in India’s case, is the current 
healthcare system. Although India is economically prospering, the healthcare sector is receiving 
an expenditure of 4.13% from the gross domestic product (GDP) (Balarajan, Selvaraj, & 
Subramanian, 2011). Comparing this GDP to other developing countries, the percentage is not 
importantly critical, but its allocation is certainly an issue of urgent assessment. From the 4.13% 
there is an allotment of just 1.10% to public health in rural and urban areas, and from this 1.10%, 
the funding disproportionately affects rural healthcare resources (Balarajan, Selvaraj, & 
Subramanian, 2011). These insufficient funds in the public health sector result in low-quality 
diagnostic and treatment services from healthcare facilities. This is especially detrimental for 
individuals of low-socioeconomic status who rely on low-cost services from the publicly run 
federal clinics. Also, rural areas are many times inadequately treated because physicians are not 
appropriately trained for the influx of infectious disease cases (Rao, Rao, Kumar, Chatterjee, & 
Sundararaman, 2011). In addition, individuals are made more vulnerable in the context of an 
unregulated pharmaceutical market put in use by both the public and private sector (Balarajan et 
al., 2011). Certainly, the private sector of India’s healthcare is also in need of reform and 
implementation of regulations, considering 70% of health workers are employed by it (Balarjan, 
et al. 2011). Considering the healthcare environment, it is evident that TB is transmitting to the 
vulnerable populations because of a need for framework reconstruction. Both India’s state and 
federal governments are essential in increasing funding, staffing rural clinics with trained 
professionals, assessing private physician qualifications, and regulating the unregulated drug 
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companies. India should be driven to invest in reconstructing a healthcare framework due to the 
increasing number of cases for MDR-TB, induced by the lack of diagnostic services and 
physicians with unpracticed skills in providing treatment. 
 
Risk Factors Affecting India’s Population 
 Furthermore, the population of India is made vulnerable by the underlying risk factors 
influenced by their social environments. Poverty has been recently recognized as an important 
feature in recognizing TB susceptible populations. Currently, India is ranked 119 out of 169 
countries based on human development and 41.8% of their population is living below the 
international poverty line (Kamineni, et al., 2012). Also, using the multidimensional poverty 
index (MPI), 8 Indian states, with a total population of 421 million, were comparable to 26 of the 
poorest African countries with a population of 410 million people (Alkire & Santos). According 
to Kamineni (et al., 2012), the five Indian states with highest proportion of their population 
living below the poverty line are Bihar, Jharkhand, Madhya Pradesh, Chattisgarh, and 
Uttarakhand. Based on the high incidence of poverty in India, it can be expected that being poor 
is a risk factor for acquiring TB and MDR-TB due to lack of finances for appropriate healthcare. 
Consequently, a recent survey done in Delhi revealed that the “poor were two times more likely 
to have TB, three times less likely to access TB care, four times less likely to complete treatment 
and many times more likely to incur impoverishing payments for TB care” (Goodchild et al., 
2010). The co-relation between poverty and health exemplifies the need for constructing a public 
health system that serves such vulnerable populations. A diseased individual who is poor has 
lack of access for healthcare because their socioeconomic status directly influences their 
nutritional status, living conditions, and their residing districts.  
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 When clinicians analyze the nutritional status of a patient, they must consider poverty as 
an important risk factor for TB and MDR-TB. Mainly, malnutrition increases the susceptibility 
of an individual because the immune system is weakened by lack of vital nutrients. In effect, 
acquiring TB is dependent on the strength of the host’s macrophages, cytokines and T-
lymphocytes, all part of a responsive healthy immune system. Studies done on TB-infected lab 
animals have reported that lack in protein calorie intake will result in enhanced bacterial growth 
(Gupta, Gupta, Atreja, Verma, & Vishkarma, 2009). There has also been linkage of protein 
deficiency leading to a dearth in the immune system’s natural process of generating antigen-
specific-immune lymphocytes when infected with disease (Gupta et al, 2009). Consequently, in 
receiving the BCG vaccine, protein deficient systems do not have the strength of acquiring 
reactive T-lymphocytes following vaccination (Gupta et al., 2009). Although it is true that 
tuberculosis alone is a debilitating disease, causing patients to waste away from the reduction in 
appetite and nutrient malabsorption, food shortages should still be considered when 
reconstructing a public health infrastructure for regions of India. Perhaps addressing malnutrition 
can prevent secondary immunodeficiency disorders that lead to the higher mortality rates of TB 
and MDR-TB.  
 Another factor arising from poverty is the overcrowded living conditions that breed 
transmission of communicable diseases like TB. Other than China, India is known to be one of 
the most overpopulated countries in the world. However, unlike China, there is no limit placed 
on the number of family members allowed per household. Nevertheless, the implementation of 
such measures is less necessary with improvement of infection control measures. Community-
based programs on infection control may prove useful for overpopulated and TB prevalent areas 
of India. Moreover, because TB is an aerosol transmitted disease, strict implementations should 
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be placed on healthcare facilities, academic facilities, and any other common areas in which 
individuals are more likely to become infected. Perhaps implementation of annual TB screening 
and DST testing should be required from healthcare professionals and other healthcare 
stakeholders. Government regulations are an important factor in keeping their populations free 
from disease through infection control and assuring effective access to qualified healthcare 
professionals. 
Lack of access to physicians experienced in treating TB is another risk factor for the poor 
and even the middle-class populations of India. Although programs such as RNTCP provide free 
care to populations of lower socioeconomic status, there is still a necessity for government 
officials to intervene regarding qualified primary care providers. Specialized training in TB risk 
factors, diagnosis, and appropriate treatment should be implemented for medical schools, private 
and public institutions. Training programs for combating TB can minimize the lack of 
knowledge between multiple providers that see TB patients outside of the RNTCP program. 
However, increasing physician knowledge about TB is only a minor step in minimizing the 
deliverance of poor healthcare. Campaigns about TB risk factors and availability of public health 
treatment programs should be delivered to all regions of India. 
 India’s health programs, for combating TB, should have the objective of increasing 
health literacy nationwide. Health literacy is an important risk factor for the impoverished 
because these are populations more rooted in traditional medications that are not keen on 
accepting drug therapy from programs such as RNTCP. In a cross-sectional community survey 
based on 30 districts of India, Satyanarayana (et al., 2011) found that the reasons people sought 
treatment outside of RNTCP were due to “poor knowledge about the disease and the services 
available.” The study also found 43% of the 30 districts to be illiterate, therefore instructions on 
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taking medication or pamphlets with information about healthcare options may have proved 
difficult for them to research and accept (Satyanarayana et al., 2011). Another study by Pinto and 
Udwadia (2010) interviewed patients from P.D. Hinduja Hospital and Research Centre in 
Mumbai, India, and found that “only 30 of 200 patients (15%) were aware of the DOTS 
[RNTCP] program.” Surprisingly, after a brief explanation of the RNTCP agenda, 91.5% of the 
patients admitted that they would rather buy treatment drugs themselves before accepting this 
type of therapy (Pinto & Udwadia, 2010). The time inconvenience, intrusion of privacy, and the 
public nature of the program were commonly cited reasons for patient disinterest in RNTCP. 
Unfortunate for RNTCP, there is a “stigma” attached to public health care in India, and many 
individuals, both literate and illiterate, believe the private sector to be best at serving their 
purpose. The private sector is believed to offer more patient privacy and more prompt as well as 
flexible services. The lack of trust of public health care in India is a “stigma” that must be 
resolved with support both from public health campaigns and the private health sector, who 
should recommend RNTCP programs to its TB-infected patients.  
 Another campaign of interest for increasing health literacy and combating infectious 
diseases in India is one regarding HIV/TB co-infection. In addition to the vulnerable populations 
from low-socioeconomic backgrounds, there is also a vast amount of individuals diseased both 
by HIV and TB. The HIV/TB co-epidemic is significantly relevant for India, because TB takes a 
fast disease course in patients with HIV with more probability of acquiring MDR-TB in a shorter 
period of time. Unfortunately, the treatment for an HIV/TB infected patient is complex, 
expensive and involves a burden of many pills with varying toxicities (Swaminathan & 
Narendran, 2008). Generally, HIV-patients infected by TB suffer from higher mortality rates 
during and after treatment (Swaminathan & Narendran, 2008). The higher mortality rate among 
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HIV/TB co-infected patients is due to the overwhelming workload being placed on an already 
vulnerable immune system. By definition, HIV is associated with a general loss of T-
lymphocytes and the immune system is less effective in maintenance of intruding pathogens 
(Swaminathan & Narendran, 2008). Consequently, a co-diseased immune system takes a quickly 
aggressive and depleting course. 
 From the identified risk factors and system disparities, it is a fact that the delivery of TB 
services cannot be an autonomous effort by existing organizations. Intervention strategies for 
combating TB must include collaborations between NTPs like RNTCP and foreign nonprofits or 
NGOs. Funding must be sought both from the national government as well as partnering 
programs interested in eliminating infectious diseases like MDR-TB. As of 2009, the treatment 
success for MDR-TB failed to reach the global target of 75% success rate (Chiang et al., 2013). 
The reported success rate was 48% (Chiang et al., 2013). Therefore, the next decade should seek 
to unite nations, foreign organizations, and nonprofits in an alliance towards establishing strong 
public health structures for all countries. The focus of the study is specific guidelines for India’s 
reconstruction and possible intervention strategies for bridging the gap in disparities among their 
TB-infected populations. 
 
RESEARCH DESIGN/METHODS 
The objective of the study was to identify effective TB treatment programs in countries 
with similar risk factors to that of India. The study used qualitative and comparative methods to 
examine the current treatment programs being used in locations with high prevalence of TB and 
MDR-TB, such as the vulnerable populations of Bangladesh, Peru, Russia, and Thailand. All of 
these countries have established TB programs because they experience prevalent TB rates and 
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have identified cases of MDR-TB. However, they have taken aggressive measures to reduce the 
burden of TB and MDR-TB. Also, with the objective of making the study more complete, it was 
necessary to assess programs not just from TB prevalent areas, but also from a country with 
record low rates for the debilitating disease. Therefore, U.S. TB programs will be analyzed for 
insight into their framework of keeping TB at less alarming percentages.  
 The populations that were chosen for the comparative study was based on their 
similarities to India’s demographics and risk factors for TB. The risk factors similar to those of 
India also arise from high percentages of poverty among their rural populations. Evidently, 
poverty influences living conditions, infection control, health literacy, and access to effective 
healthcare facilities with appropriate laboratory equipment to mitigate the time between 
diagnosis and treatment. Most effective healthcare facilities arise from strong government 
regulations and surveillance systems. Among the populations that will be studied, laboratory 
technology ranges from best to most minimal access. The U.S. is the known to have some of the 
best laboratory diagnostics available to them, whereas Bangladesh, Peru, Russia, and Thailand 
are steadily recognizing the importance of healthcare expenditure on quick diagnostic procedures 
for TB/MDR-TB.  
 The research conducted was based on mainly primary and secondary sources. Primary 
sources were gathered from studies that were previously conducted to gather statistics about the 
effectiveness of the programs mentioned. Generally, databases such as ProQuest were used to 
identify scientific journals such as The Lancet’s Infectious Diseases, PLoS ONE and reports 
from WHO as well as CDC. The keywords used in searching for relevant and up-to-date 
information were as follow: “tuberculosis AND intervention AND programs,” “tuberculosis 
AND Bangladesh,” “tuberculosis AND Peru AND initiatives,” “tuberculosis AND Russia AND 
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prisons,” “tuberculosis AND Thailand AND programs,” “tuberculosis AND global AND 
programs,” “tuberculosis AND U.S. AND epidemic,” “U.S. AND public health,” “tuberculosis 
AND partners in health,” and other searches using keyword variations. Articles of interest were 
those with valuable statistics or discussions of outcomes from effective TB/MDR-TB programs 
in any of the locations of interest.  
 In analyzing the gathered information, statistics were partially important for measuring 
the effectiveness of a program by quantitative measures and examining whether or not the 
program achieved their target goal and was effective. However, findings and discussion sections 
were more importantly analyzed for the followings: community intervention programs, adequate 
access to healthcare facilities, and deliverance of appropriate treatment programs, strengthening 
of surveillance systems, and government agency initiatives. Evaluation of the gathered 
qualitative results should give insight to India’s current lack of unity among their deliverance of 
healthcare diagnosis, treatment, and prevention to TB infected individuals. The purpose is to 
provide India with examples of intervention programs that can possibly strengthen their current 
public health system.  
 
FINDINGS/RESULTS 
Bangladesh’s TB Campaigns  
 Bangladesh is a country in South Asia and is bordered by part of India. There is a large 
rural population that lives in villages accustomed to traditional lifestyles and their urban 
population is recognized as the 7th largest population in the world (Global Health Initiative). In 
2005, Bangladesh was one of the most burdened TB countries in the world and launched a 
community-based TB campaign for delivering public health awareness (Rifat et al., 2008). As a 
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collaborative effort between a nongovernmental organization (NGO) and Bangladesh’s NTP, 
known as Fund for Innovative DOTS Expansion through Local Initiatives to Stop Tuberculosis 
(FIDELIS), the program delivered TB information to 27.56 million people in 10 rural districts of 
Bangladesh (Rifat et al., 2008). Information about TB was reported through theater 
performances, in classroom settings of primary schools, in mosques, at small group meetings, 
and through television messages (Rifat et al., 2008). The mobilizing campaign increased TB case 
detection by 36%, compared to the 29% from other districts that did not implement the same 
measures (Rifat et al., 2008). Certainly, conveyance of cumbersome TB information was made 
more amusing by the animated activities from the campaign. These types of public health 
awareness campaigns are vitally important for all low-income countries in need of infection 
control. Programs must be structured in a manner that appeals to the community culture and they 
must not be threatening in any way. Community-based initiatives such as this communicate TB 
risk factors, forms of transmission, and importance of receiving medical check-ups in a more 
effective manner because the community engages. Also, health literacy is drastically increased 
when community leaders are able to translate information to adequate dialogues in the simplest 
manner. As mentioned before, India’s government must invest in a nationwide campaign 
regarding TB. Leaders from high TB burdened communities must receive proper training in how 
to best deliver TB information regarding prevention, diagnosis and treatment. The cost-
effectiveness of this program is not known, but preventing cases of MDR-TB from surfacing 
saves funds on second-line medical treatments. A TB campaign to increase health literacy in 
India is especially important for its disadvantaged communities that are unaware of NTPs or the 
dangers of being diseased with MDR-TB. 
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Lima, Peru’s New Database 
 Like India, Peru experiences a high incidence of TB globally and is the highest TB-
infected country of South America (Fraser et al., 2012). During 1995, Lima identified 12 cases of 
MDR-TB and began a reform in healthcare (Fraser et al., 2011). In attempts to combat their 
grave MDR-TB problem, Partner in Health (PIH) partnered with a sister organization by the 
name of Socios En Salud and delivered home-based DOT treatment to the diseased community 
(Fraser et al., 2011). Resulting from these first initiatives were further partnerships with other 
stakeholders, such as Ministry of Health (MOH) and The Massachusetts State Laboratory 
Institute (MSLI) (Fraser et al., 2011). Recently, another partnership with the National Institutes 
of Health (NIH) has resulted in great technological advances for Lima. The NIH provided 
funding to Lima for establishing an electronic medical record system with the objective of 
tracking patterns of the disease (Fraser et al., 2011). The program is cost-effective for countries 
with low-resources and has an encoding application for the implementation of foreign languages 
(Fraser et al., 2011). The system is called OpenMRS, and with the training of three Peruvian 
programmers, the system could be implemented and launched in September of 2009 (Fraser et 
al., 2011). OpenMRS was established with the objective of tracking the patterns of TB on one 
database that would allow for accurate documentation of disease outbreaks in households and 
other research data collection (Fraser et al., 2011). Information has not been well researched in 
regards to the engineering technicalities underlying the implementation of such a database. 
However, India’s programmers are innovative and with sufficient funding, a database that would 
track TB-case reports can deliver an accurate nationally based record on disease patterns and 
areas to implement intervention programs. 
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Tomsk, Russia’s ‘Sputnik’ TB Program 
 Similar to India, Russia forms part of BRIC, the quickly developing global economies, 
and is also combating a TB epidemic. Tuberculosis risk factors similar to those of India are 
poverty and a minimally integrated public health system with a dearth in healthcare professionals 
to access all regions. Also, Russia experiences a high-burden of mortality due to drug-abuse and 
crime as well as high TB-rates among their prisoners (Gelmanova, 2011). The disintegration of 
the public health in Russia occurred following the collapse of the Soviet Union and an 
overcrowding in their prisons cultured the overwhelming TB epidemic (Pickett, 2012). However, 
through much delegation with the political agenda of Russia, Partners In Health (PIH) became a 
key foundation for the establishment of national tuberculosis initiatives. Partners in Health 
assisted in establishing TB control procedures in the prison systems of Russia and provided 
training to laboratory as well as medical professionals. Also, the integration of Partners in 
Health, a nonprofit, has recently partnered with Russia’s Health Ministry to launch a program by 
the name of ‘Sputnik.’  
 The ‘Sputnik’ program was established in December of 2006 in Tomsk, Russia, with the 
objective of increasing the adherence of MDR-TB infected patients (Partners in Health, 2011). 
Sputnik uses a home-based therapy approach with healthcare professionals who visit MDR-TB 
identified patients who are at high risk for non-adherence and provide treatment (Gelmanova et 
al., 2011). After analyzing treatment adherence, Gelmanova (et al., 2011) found the “cure rate [to 
be] 71.1% for patients with MDR-TB, 60% for all others, and 68% in the program overall” (p. 
1373). The study also found the cost of treating a Sputnik patient to be “U.S. $6.50 per day, 
where the cost of the alternative- in-patient care for the duration of treatment- ranges from U.S. 
$9.30 per day to as high as U.S.$35.00 per day” (Gelmanova et al., 2011, p. 1377). Furthermore, 
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replication of Sputnik in other cities would require funding for ambulatory vehicles, training of 
professionals, and purchase of both first as well as second line MDR-TB treatment regimens. For 
India, a study needs to be done to calculate the cost-effectiveness for the possibility of 
implementing such a program. The program could prove beneficial for treating MDR-TB 
patients in rural areas of India who are at higher risk for non-adherence. Also, before 
implementation of a Sputnik-style approach, India needs to increase awareness about the risks of 
TB to populations who may be illiterate or need more information on why compliance to 
treatment can save their life and the lives of those around them. India could also benefit from 
partnering with nonprofit organizations seeking to make an effective change in the TB-infected 
communities.  
 
Thailand’s Surveillance Network 
 During 2006, Thailand ranked as the 18th most TB burdened country in the world (Varma 
et al., 2007). Some risk factors for Thailand’s population that are similar to India’s are 
socioeconomic factors as well as the HIV/TB co-infection epidemic. Following WHO’s Global 
Plan to Stop TB 2006- 2015, Thailand mobilized their TB Active Surveillance Network in 
October of 2004 with the target of drastically reducing the percentage of TB burden (Varma et 
al., 2007). According to the study by Varma (et al., 2007), the Thailand TB Active Surveillance 
Network collaborates with “Thailand’s Ministry of Health of Public Health, the Bangkok 
Metropolitan Administration, the United States Centers for Disease Control and Prevention, and 
the Research Institute of Tuberculosis Japan.” Similarly to the countries previously described, 
the TB program in Thailand is also dependent on collaborations with national and foreign 
stakeholders. The program focuses on collecting all reported TB cases from both public and 
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private healthcare facilities in order to best measure the effects of programs such as DOTS. The 
staff from Thailand’s healthcare facilities of selected districts uses an electronic database and 
securely delivers information to the national TB program (Varma et al., 2007). Overall, the TB 
program of Thailand is successful in reporting TB cases in Thai citizens, but the limitation of the 
reporting system is that it has minimal reports for non-Thai migrants who migrate from TB 
endemic places like Cambodia and Myanmar (Varma et al., 2007). Regardless, Thailand’s 
surveillance system for TB is another example of technology able to record epidemiological 
significant data. As referenced previously, India must establish a surveillance system with a 
public-private collaboration effort, in order to accurately identify disease outbreaks such as TB 
and MDR-TB.  
 
U.S. Public Health Model 
 Unlike the developing countries previously described, the U.S. experiences fairly low 
rates of TB. In 2011, a national TB record low rate was reported to be an incidence of 3.4 cases 
per 100,000 population (Centers for Diseases Control and Prevention, March 2012). Assessment 
for an explanation of the low TB rates in the U.S. may be useful for developing countries. 
Research about U.S. intervention strategies may provide a framework that may help improve 
their current TB program models. Tuberculosis intervention strategies of the U.S. are 
dependable, insofar as, historically the U.S. has achieved milestones in combating this infectious 
disease. During the 17th century and again in 1985, TB accounted for a large percentage of the 
mortality rates in the U.S. (Schneider, 2004). Therefore, from 1985 to recently, the U.S. 
advanced from one of the highest to one of the lowest rates of TB worldwide. Many of the 
advancements that aided the U.S. in their TB struggle were due to strong public health measures 
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demanding the improvement for living conditions of the poor (Schneider, 2004). Additionally, in 
the early 1990s, a large outbreak of MDR-TB in New York City resulted in immediate political 
involvement in terms of funding prevention, diagnostic, and treatment programs (Abubakar et 
al., 2013). Certainly, intensive public health measures are the explanation for why the U.S. was 
able to drastically decrease their TB rates. Also, much political involvement and government 
funding allowed for the implementation of surveillance and monitoring systems with the intent 
of preventing any further outbreaks. The U.S. public health infrastructure is intrinsic and 
involves many stakeholders, systems, and organizations all working towards maintaining a 
healthy population. Currently the CDC provides the U.S. public health infrastructure with 
infection control guidelines that include surveillance, response, applied research, training, 
prevention, and control (Schneider, 2004).  
Nevertheless, a 2010 report found that foreign-born persons accounted for 60% of all TB 
cases in the U.S. (Woodruff et al., 2013). The upcoming challenges for the U.S. healthcare 
system involve more research for “understanding cultural competency in health practice” 
(Woodruff et al., 2013). In general, developing countries like India should fund research 
programs that may prove cost-effective for their overall national healthcare system. Funding 
healthcare initiatives that will increase health literacy through community-based awareness 
programs will result in prevention and early diagnosis for TB. Investing further funding in a 
surveillance and monitoring system will allow for rapid recognition of disease outbreaks, rather 
than the current gap between outbreak and action. Lastly, although RNTCP has proved helpful in 
treating some TB outbreaks, “NTPs cannot be operated as stand-alone interventions (Chiang et 
al., 2013). Strengthening of public health systems is fundamental and imperative for the 
prospective decade of effecting change in TB programs and healthcare facilities.    
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CONCLUSION/IMPLICATIONS 
 Resulting from the assessment of India’s current difficulty with controlling their TB 
epidemic, it was necessary to seek TB intervention programs in countries similar to India who 
are gradually building their public health framework. A thorough review of literature identified 
the grave social inequities affecting a large percentage of India’s TB infected population. The 
poor are disproportionately affected by malnourishment, overcrowded living conditions, and lack 
of access to adequate TB diagnostic facilities. Moreover, Indian citizens are affected by a 
disintegrated healthcare system with gaps in communication between the public and private 
sectors that produces an ideal environment for the development of MDR-TB. Advantageous to a 
structure that neglects regulations on pharmaceuticals is a lack of advanced laboratory 
technology. Monitoring and keeping patient records on a national surveillance system is absent 
from India’s public health infrastructure. Using a surveillance system for detecting outbreaks and 
developing intervention programs based on disease patterns has proved beneficial to places such 
as Lima and Thailand. Furthermore, integration of the public-private sectors of India may allow 
for better control of HIV/TB co-infected patients who consume a toxic level of various treatment 
drugs and have higher susceptibility for acquiring MDR-TB as well as more prevalent mortality 
rates.  
 Having concluded a further examination of other countries, with abundant TB rates and 
similar risk factors to that of India, it is possible to consider the need for India to establish further 
collaborations with foreign organizations as well as NGOs. An unfavorable limitation in 
completing a general cross-analysis between Bangladesh, Peru, Russia, and Thailand with India 
was the absence of studies examining cost-effectiveness of establishing their TB programs. Also, 
most studies that were found through the ProQuest database were in regards to individual studies 
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focusing on collaborations between country NTPs and nonprofits. There was a gap in 
information concerning the actual public health system of most of the evaluated countries. 
Furthermore, reviewing for literature about India, RNTCP-DOTS was the only TB program 
found that paralleled all DOTS programs in the other countries. Principally, studies of other 
countries suggested the following guidelines: 1) Establishment of a surveillance system; 2) 
engaging the community with TB awareness campaigns; and 3) Strengthen NTPs with 
collaborations from foreign establishments such as PIH. In addition, evaluation of the U.S. 
public health initiative for infection control offers India a guideline for the integration of many 
departments working towards a single objective.  
 Future studies should focus on researching cost-effective measures that can be 
implemented in laboratory settings of all developing and underdeveloped countries. Attempting 
to replicate the U.S. system for diagnostic purposes would be ineffective for countries combating 
a much more aggressive outbreak of TB. More specifically, developing countries need to rely 
more heavily on DST testing services rather than culturing bacteria that would further delay the 
time between diagnosis and treatment. Innovations such as the recent Xpert MTB/RIF assay may 
prove to be more reliable for identifying MDR-TB and cost-effective for low as well as middle-
income countries. More research should be done regarding the replication of Xpert assay in 
countries experiencing outbreaks of MDR-TB. 
 Also, more research must be done for further evidence that community engagement may 
drastically decrease TB incidence rates. Most of the studies evaluated in this paper involve 
communicating knowledge to certain regions about their TB diagnosis and treatment. In 
Bangladesh, for example, TB campaigns were integrated into the daily living activities of its 
inhabitants. Integration of TB knowledge into the daily day of a child or adult helps increase 
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health literacy from one generation to the next. According to the CDC, community engagement 
is defined as, “the process of working collaboratively with and through groups of people 
affiliated by geographical proximity, special interest, or similar situations to address issues 
affecting the wellbeing of those people” (Boulanger et al. 2013).  Aside from NTPs and NGOs 
that are more likely to include community engagement activities, combating the MDR-TB 
epidemic will also require the support from the general public health infrastructure and 
regulations for ensuring qualified physicians and authenticate treatment TB drugs. 
 In conclusion, models for combating emerging diseases should be effective innovations 
worldwide. As mentioned before, the government must increase funding for diagnostic services, 
community engagement, and further research on how equitable care can be distributed by the 
public health infrastructure of India. Tuberculosis is a treatable disease and the prevalence of 
mortality can be changed with dedication and commitment to public health programs against the 
transmittable bacteria.  
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